It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATNF’s FA Score shows that 0 FA rating(s) are green whileCYCC’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATNF’s TA Score shows that 2 TA indicator(s) are bullish while CYCC’s TA Score has 3 bullish TA indicator(s).
ATNF (@Biotechnology) experienced а -8.53% price change this week, while CYCC (@Biotechnology) price change was -7.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -5.92%. For the same industry, the average monthly price growth was -3.16%, and the average quarterly price growth was +1.65%.
ATNF is expected to report earnings on Mar 01, 2023.
CYCC is expected to report earnings on Mar 27, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ATNF | CYCC | ATNF / CYCC | |
Capitalization | 2.75M | 846K | 325% |
EBITDA | N/A | N/A | - |
Gain YTD | -33.933 | -85.270 | 40% |
P/E Ratio | N/A | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | 676K | 3.3M | 20% |
Total Debt | 789K | 21K | 3,757% |
ATNF | CYCC | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 94 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 35 | 98 | |
P/E GROWTH RATING 1..100 | 97 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CYCC's Valuation (19) in the Biotechnology industry is somewhat better than the same rating for ATNF (52) in the Financial Conglomerates industry. This means that CYCC’s stock grew somewhat faster than ATNF’s over the last 12 months.
CYCC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATNF (100) in the Financial Conglomerates industry. This means that CYCC’s stock grew similarly to ATNF’s over the last 12 months.
CYCC's SMR Rating (99) in the Biotechnology industry is in the same range as ATNF (100) in the Financial Conglomerates industry. This means that CYCC’s stock grew similarly to ATNF’s over the last 12 months.
ATNF's Price Growth Rating (35) in the Financial Conglomerates industry is somewhat better than the same rating for CYCC (98) in the Biotechnology industry. This means that ATNF’s stock grew somewhat faster than CYCC’s over the last 12 months.
ATNF's P/E Growth Rating (97) in the Financial Conglomerates industry is in the same range as CYCC (100) in the Biotechnology industry. This means that ATNF’s stock grew similarly to CYCC’s over the last 12 months.
ATNF | CYCC | |
---|---|---|
RSI ODDS (%) | 2 days ago72% | 2 days ago90% |
Stochastic ODDS (%) | 2 days ago79% | 2 days ago83% |
Momentum ODDS (%) | 2 days ago78% | 2 days ago90% |
MACD ODDS (%) | 2 days ago82% | 2 days ago90% |
TrendWeek ODDS (%) | 2 days ago88% | 2 days ago90% |
TrendMonth ODDS (%) | 2 days ago63% | 2 days ago88% |
Advances ODDS (%) | N/A | 8 days ago0% |
Declines ODDS (%) | 2 days ago90% | 4 days ago88% |
BollingerBands ODDS (%) | N/A | 2 days ago90% |
Aroon ODDS (%) | N/A | N/A |
A.I.dvisor indicates that over the last year, ATNF has been loosely correlated with PRQR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNF jumps, then PRQR could also see price increases.
Ticker / NAME | Correlation To ATNF | 1D Price Change % | ||
---|---|---|---|---|
ATNF | 100% | -7.27% | ||
PRQR - ATNF | 46% Loosely correlated | -0.25% | ||
CTCX - ATNF | 42% Loosely correlated | +3.41% | ||
KRRO - ATNF | 39% Loosely correlated | -9.65% | ||
WVE - ATNF | 35% Loosely correlated | -4.40% | ||
PHMMF - ATNF | 33% Poorly correlated | N/A | ||
More |
A.I.dvisor tells us that CYCC and ONPPF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYCC and ONPPF's prices will move in lockstep.
Ticker / NAME | Correlation To CYCC | 1D Price Change % | ||
---|---|---|---|---|
CYCC | 100% | -12.60% | ||
ONPPF - CYCC | 23% Poorly correlated | N/A | ||
GNPX - CYCC | 23% Poorly correlated | +2.50% | ||
BPTSY - CYCC | 21% Poorly correlated | N/A | ||
NGENF - CYCC | 21% Poorly correlated | -19.27% | ||
ATNF - CYCC | 21% Poorly correlated | -7.27% | ||
More |